Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Pharmaxis.
RELATED STOCKHEAD STORIES
Health & Biotech
Dr Boreham’s Crucible: Why CSL is the poster child for most junior drug developers
News
Weekly ASX small cap wrap: Who got a bit too silly in the silly season this week?
News
Lunchtime ASX small cap wrap: Who’s taking an early break today?
Health & Biotech
Health: Pharmaxis partner quits NASH drug development, shares halve
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Health: Is this the big news from Germany Pharmaxis was waiting for?
Experts
On the Radar: 5 small caps that brokers pick for growth in the months ahead
Health & Biotech
The health sector has been the ASX’s top performer in 2019, but could a recession stop it in its tracks?
Health & Biotech
These are the 22 small cap biotechs closest to bringing a drug to market
Health & Biotech
Health: Resonance Health says cash receipts continue to grow, but investors are looking for more
Health & Biotech
